Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data

I covered Xenon Pharmaceuticals Inc. (NASDAQ: XENE ) in August. Then, I noted that lead asset azetukalner (XEN1101) was running phase 3 clinical trials targeting two forms of epilepsy, focal onset seizure (FOS’) and Primary Generalized Tonic-Clonic Seizures (PGTCS), and a phase 3 trial called X-NOVA2About the TPT ServiceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where yo ...